Avodart and Flomax provided better relief from three months to 24 months of treatment, Glaxo said at a urology conference in Paris found. The company, Europe’s largest drugmaker, plans to submit the findings to the U.S. Food and Drug Administration. Closely held Boehringer co-markets Flomax with Astellas Pharma Inc. of Japan.
Half of men over 50 years old and more than 90 percent of men older than 80 suffer from enlarged prostate. The condition can cause a frequent urge to urinate or difficulty emptying the bladder. Severe cases may require surgery.
The trial also showed that patients taking Avodart alone continued to experience improvement over 24 months and progress in those given Flomax leveled off after three months, Glaxo said. The four-year study enrolled 4,800 men and is continuing, the company said.